Successful clinical translation of Wave's RNA medicines platform in HD patients with WVE-003 provides further validation of Wave's proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval Dystrophin data on track for 3Q 2024 from potentially registrational FORWARD-53 trial of WVE-N531, which has previously demonstrated industry-leading exon skipping of 53%; positive data ...

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 8, 2024, to review the company's second quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other juris ...

临床试验进展 - 公司正在推进AATD项目WVE-006的RestorAATion-2临床试验，预计2024年将获得机制验证数据[3][4] - 公司正在推进INHBE项目的临床试验，预计2025年第一季度启动临床试验，该项目具有潜在的最佳在类地位[6][7][8][9][10] - 公司的杜氏肌营养不良(DMD)项目FORWARD-53正在推进，预计2024年第三季度获得可能具有注册意义的24周肌肉蛋白表达数据[13][15] - 公司的亨廷顿氏病(HD)项目WVE-003的SELECT-HD多剂量数据有望在2024年第二季度公布，这是一个首创的针对性降低突变型HTT蛋白而保留野生型HTT蛋白的疗法[16][17][18][20] 合作项目进展 - 公司与GSK的合作持续推进，已推进首两个合作项目进入开发候选物阶段，这些项目使用公司的GalNAc-siRNA技术[11][12] 财务状况 - 公司现金及现金等价物为18.0922亿美元[29] - 公司总资产为23.527亿美元[29] - 公司总负债为20.2007亿美元[29] - 公司研发费用为3.3447亿美元[31] - 公司一季度营收为1.2538亿美元[31] - 公司一季度净亏损为3.1558亿美元[31] - 公司一季度每股亏损为0.24美元[31] - 公司一季度研发费用为3.3447亿美元[31] - 公司一季度管理费用为1.3549亿美元[31] - 公司一季度其他收益净额为2900万美元[31]

Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2023 Earnings Call Transcript March 6, 2024 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Timur Ivannikov - Raymond James Salim Syed - Mizuho Joon Lee - Truist Joseph Schwartz - Leerink Partners Luca Issi - RBC Capital Andrew Fein - H.C. Wainwright ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore 98-1356880 (State or other jurisdiction of i ...

Exhibit 99.1 Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025 Dose escalation ongoing in RestorAATion-1 clinical trial of WVE-006, industry's first-ever RNA editing candi ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Salim Syed - Mizuho Joseph Schwartz - Leerink Partners Eun Yang - Jefferies Operator Good morning and welcome to Wave Life ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Singapore (State or other jurisdiction of incorporation or organization) 7 Straits View #12-00, Marina One East Tower Singapore Commission F ...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President and Chief Executive Officer Anne Cheung - Chief Development Officer Kyle Moran - CFO Conference Call Participants Steven Seedhouse - Raymond James Julian Pino - Stifel Eun Yang - Jefferies Salim Syed - Mizuho Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2023 Financial Results Conference Call. [Opera ...